Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Clinical evidence

ABX464-902

30 evidence topics · 4 sources

Objective
Location and study date
Study dates and status in the registry record
FieldRegistry entry
Recruitment status“Completed”
Study start (actual)“2020-12-17”
Primary completion (actual)“2021-05-18”
Results reporting dates in the registry record
FieldRegistry entry
Results first submitted“2022-05-06”
Results first posted“2026-11-09”
Other study ID numbers“ABX464-902”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using caffeine and Obefazimod cmax and AUC as the primary endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Participant flow in the registry results
MilestonePart APart B
Started“24”“35”
Completed“24”“34”
Withdrawal by subject“0”“1”
Baseline characteristics
Age and sex by study part
Efficacy results
Part A: caffeine exposure with and without obefazimod (PK analysis set, 22 participants)
Measure, mean (standard deviation)Day 1, caffeine aloneDay 4, caffeine and ABX464Day 17, caffeine and ABX464
Caffeine Cmax, ng/mL“931(285)”“930(278)”“564(242)”
Caffeine AUC, h*ng/mL“7420(4760)”“5460(2740)”“1560(719)”
Part B: obefazimod exposure with and without fluvoxamine (PK analysis set, 25 participants)
Measure, mean (standard deviation)Day 1, ABX464 aloneDay 11, ABX464 and fluvoxamine
ABX464 Cmax, ng/mL“23.2(12.5)”“33.4(19.0)”
ABX464 AUC, h*ng/mL“55.2(25.7)”“73.0(34.2)”
Health-related quality of life and patient-reported outcomes

Not applicable.

Safety results
Adverse events, serious adverse events, and deaths
MeasurePart A overallPart B overall
Participants with any other (nonserious) adverse event“16/24 (66.67%)”“30/35 (85.71%)”
Participants with a serious adverse event“0/24 (0.00%)”“0/35 (0.00%)”
Most frequent adverse events by study part
Study limitations
Summary

ABX464-902 enrolled 59 healthy adults in the United Kingdom (24 in Part A and 35 in Part B) and has no peer-reviewed publication. The registry results, first submitted in May 2022 and posted in November 2026, give means and standard deviations only. The protocol specified geometric least squares mean ratios with 90% confidence intervals, and neither the registry nor any other public source reports them. In Part A, the posted mean caffeine AUC was 7420 hng/mL on Day 1 alone and 1560 hng/mL on Day 17 after 14 days of obefazimod, and mean Cmax was 931 and 564 ng/mL; the HRA plain-language summary states that caffeine levels “remained similar in both the presence and absence of ABX464”, and the registry gives no analysis that reconciles the two. In Part B, mean obefazimod Cmax and AUC were higher with fluvoxamine (33.4 against 23.2 ng/mL and 73.0 against 55.2 h*ng/mL), and the HRA summary states that obefazimod “may be metabolised in the same pathway as fluvoxamine”. Nine of 35 Part B participants were excluded from the pharmacokinetic analysis for vomiting and one for early withdrawal; the registry states that these exclusions “did not impact on the overall evaluation of the study objectives”. No metabolite (ABX464-N-glucuronide) result is posted, Part B used single 50 mg doses of obefazimod, and race and ethnicity were not collected.